about
Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer.Efficacy of adjuvant chemotherapy in early stage uterine leiomyosarcoma: A systematic review and meta-analysis.Chemotherapy-related leukopenia as a biomarker predicting survival outcomes in locally advanced cervical cancer.Morcellation worsens survival outcomes in patients with undiagnosed uterine leiomyosarcomas: A retrospective MITO group study.Multimodal treatment of advanced renal cancer in 2017.ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer.Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study.Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING case-control study.Preoperative Capecitabine, Oxaliplatin, and Irinotecan in Resectable Gastric or Gastroesophageal Junction Cancer: Pathological Response as Primary Endpoint and FDG-PET Predictions.Castration-naive metastatic prostate cancer: reshaping old paradigms.RET fusions in a small subset of advanced colorectal cancers at risk of being neglected.Exposure to Multiple Lines of Treatment and Survival of Patients With Metastatic Renal Cell Carcinoma: A Real-world Analysis.TARIBO trial: targeted therapy with or without nephrectomy in metastatic renal cell carcinoma: liquid biopsy for biomarkers discovery.Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II clinical study.Low Baseline Serum Sodium Concentration Is Associated with Poor Clinical Outcomes in Metastatic Non-Small Cell Lung Cancer Patients Treated with ImmunotherapyInnovative therapy, monoclonal antibodies, and beyond: Highlights from the eighth annual meetingEstimating Survival Probabilities of Advanced Gastric Cancer Patients in the Second-Line Setting: The Gastric Life NomogramThe landscape of d16HER2 splice variant expression across HER2-positive cancersModulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitorsPrognostic impact of ATM mutations in patients with metastatic colorectal cancerBenefit from anti-EGFRs in and wild-type metastatic transverse colon cancer: a clinical and molecular proof of concept studyEnhancing Chimeric Antigen Receptor T cell Efficacy in Solid TumorsImmunotherapy-based combinations: an updateWeighing the prognostic role of hyponatremia in hospitalized patients with metastatic solid tumors: the HYPNOSIS studyRET rearrangements define a new and rare molecular subtype of metastatic colorectal cancer (mCRC)Selecting patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of MGMTIndividual Patient Data Meta-Analysis of the Value of Microsatellite Instability As a Biomarker in Gastric CancerNegative Hyperselection of Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance TherapyPrognostic and Predictive Value of Microsatellite Instability, Inflammatory Reaction and PD-L1 in Gastric Cancer Patients Treated with Either Adjuvant 5-FU/LV or Sequential FOLFIRI Followed by Cisplatin and Docetaxel: A Translational Analysis from tTreatment Outcomes and Sensitivity to Hormone Therapy of Aggressive Angiomyxoma: A Multicenter, International, Retrospective StudyImpact of systemic and tumor lipid metabolism on everolimus efficacy in advanced pancreatic neuroendocrine tumors (pNETs)Perioperative Bevacizumab-based Triplet Chemotherapy in Patients With Potentially Resectable Colorectal Cancer Liver MetastasesRefining the selection of patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of O6-methylguanine-DNA-methyltransferaseA High-Avidity T-cell Receptor Redirects Natural Killer T-cell Specificity and Outcompetes the Endogenous Invariant T-cell ReceptorIs a pharmacogenomic panel useful to estimate the risk of oxaliplatin-related neurotoxicity in colorectal cancer patients?Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal CancerPrognostic Impact of Microsatellite Instability in Asian Gastric Cancer Patients Enrolled in the ARTIST TrialInvestigating the concordance in molecular subtypes of primary colorectal tumors and their matched synchronous liver metastasisAssociation between antibiotic-immunotherapy exposure ratio and outcome in metastatic non small cell lung cancerRole of Chemotherapy, VEGFR Inhibitors, and mTOR Inhibitors in Advanced Perivascular Epithelioid Cell Tumors (PEComas)
P50
Q38706872-8E082D8B-27FF-4CB4-9E88-C88644A1CCB1Q38915667-99D82E98-1CB7-4254-8050-AE09DD40450BQ39152563-01719568-CBFD-41B6-B459-DE1F416B7FD0Q39211467-EA018859-130A-4292-B35B-C91D5AC8508EQ47550490-D961088E-8EA6-4C12-8CAF-E1EFC5F88BC9Q49691234-10E68649-A923-4E4E-B445-5803E83703D5Q50058854-ABD0147B-9615-4369-9B35-FD6B7F84B7C0Q50089419-B7FB683C-2CD9-426B-80C6-F74A73B22880Q50206050-B9763062-432B-4E65-82BE-0946FEB36EBCQ50270201-6001E028-23DD-485E-BC97-2755F2F019C8Q52655893-7BF6A0DE-1CFC-4794-A5D0-A3506312D29DQ52686179-8F8889DD-A034-48D6-A53B-453EFB4F4538Q52764218-EFA82812-E157-4363-A671-B9C33A6488C6Q55689035-EF8E38D5-3FC2-4EF4-874D-FDAA5F67A1A8Q57286688-BA2F60AA-02E8-4581-8026-F9EC7AB3F403Q58590757-A48FB2D7-609A-460A-A50C-26A0C03FF181Q61054483-59750283-A717-4ABF-986C-7490C31628A6Q64065309-61FDA980-53E8-493A-87A4-B6BE9601CDDDQ64094662-39699036-A22A-4FAA-97D0-554891FC2F34Q64097897-FF57786C-F11F-4974-A724-D08EE03E30C9Q64114213-A0BC791E-08C4-4A48-8E7A-C4E52D7F5FD4Q89517158-4711872C-3850-46AF-B234-0551BFC0A91FQ89561872-DEA35F13-3E3C-4E1A-B56D-C255524C3B3FQ90045641-EC424010-9A9D-401E-AB88-A1245527B773Q90068672-82D41055-67DC-4A41-8A1F-92B2A84F4372Q90070993-2C472E42-8402-46F2-9094-327C12B9FCD5Q90076232-B72804A1-6284-4D41-BFBF-D338DC5899BAQ90190001-994E797A-4596-4E44-92E3-8C9C35616622Q90257564-CE720DFC-AB9E-40BD-BFAE-A774075E2689Q90286887-63A737AD-808D-4E5E-AA3A-16F60DA952EAQ90296046-79B8E9BB-2B08-4E9E-B9B2-D73251A15D06Q90592695-F86B491D-DB5D-47F8-ADE2-395FE79DAEF0Q90716197-BB7658F3-7D99-4BC8-8A6C-6AC12AE4A98CQ91258742-E71D3EBF-8277-43C4-8C17-0175407D69E9Q91322925-E97F2E7B-2070-4000-BCFC-2A0CC74FE8C8Q91329177-F0E55920-33E8-4F70-8E1E-03ED5AC35B3EQ91711780-F1655E8C-0A03-404E-9C6B-2BF65AAE29EBQ91748966-46ADC69C-EFF3-405D-8FD2-D03936EC883AQ92086431-150804F9-8DCD-4876-9B45-A8C39CE844FAQ92883105-5EA048EE-176F-47D1-8E88-EC30D3C69BEF
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Giovanni Fucà
@ast
Giovanni Fucà
@en
Giovanni Fucà
@es
Giovanni Fucà
@nl
Giovanni Fucà
@sl
type
label
Giovanni Fucà
@ast
Giovanni Fucà
@en
Giovanni Fucà
@es
Giovanni Fucà
@nl
Giovanni Fucà
@sl
prefLabel
Giovanni Fucà
@ast
Giovanni Fucà
@en
Giovanni Fucà
@es
Giovanni Fucà
@nl
Giovanni Fucà
@sl
P106
P21
P31
P496
0000-0002-1560-2253